Latest Insider Transactions at Perrigo CO PLC (PRGO)
This section provides a real-time view of insider transactions for Perrigo CO PLC (PRGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PERRIGO Co plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PERRIGO Co plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-6.11%
|
$19,488
$28.09 P/Share
|
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,881
+14.17%
|
$52,668
$28.09 P/Share
|
|
Mar 06
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,267
-9.53%
|
$35,476
$28.09 P/Share
|
|
Mar 06
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,870
+26.81%
|
$136,360
$28.09 P/Share
|
|
Mar 06
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-3.52%
|
$17,136
$28.09 P/Share
|
|
Mar 06
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+10.45%
|
$56,840
$28.09 P/Share
|
|
Mar 06
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
3,788
+3.82%
|
$106,064
$28.09 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,262
-4.14%
|
$34,074
$27.26 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
2,490
+13.38%
|
$67,230
$27.26 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,698
+10.72%
|
$45,846
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,178
-6.71%
|
$112,806
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
11,806
+26.09%
|
$318,762
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,071
+8.51%
|
$55,917
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,458
-6.92%
|
$120,366
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
7,291
+17.93%
|
$196,857
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,279
+4.56%
|
$34,533
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,519
-12.48%
|
$149,013
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,028
+27.46%
|
$243,756
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,583
+9.19%
|
$42,741
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,660
-21.83%
|
$125,820
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
9,652
+41.62%
|
$260,604
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,693
+27.27%
|
$45,711
$27.26 P/Share
|
|
Mar 05
2024
|
Svend Andersen EVP & President CHCI |
BUY
Grant, award, or other acquisition
|
Direct |
19,445
+17.51%
|
$525,015
$27.26 P/Share
|
|
Mar 05
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
3,411
+4.51%
|
$92,097
$27.26 P/Share
|
|
Mar 01
2024
|
Robert Willis EVP & CHRO |
BUY
Open market or private purchase
|
Direct |
371
+1.44%
|
$9,646
$26.3 P/Share
|
|
Feb 29
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,545
+11.04%
|
$40,170
$26.44 P/Share
|
|
Feb 29
2024
|
Robert Willis EVP & CHRO |
BUY
Open market or private purchase
|
Direct |
6,000
+19.29%
|
$150,000
$25.87 P/Share
|
|
Feb 29
2024
|
Patrick Lockwood Taylor CEO |
BUY
Open market or private purchase
|
Direct |
9,500
+31.67%
|
$247,000
$26.54 P/Share
|
|
Nov 24
2023
|
Robert Willis EVP & CHRO |
BUY
Open market or private purchase
|
Direct |
5,550
+22.51%
|
$172,050
$31.01 P/Share
|
|
Nov 16
2023
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
2,040
+16.43%
|
$59,160
$29.34 P/Share
|
|
Nov 14
2023
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+37.24%
|
$145,000
$29.18 P/Share
|
|
Nov 14
2023
|
Patrick Lockwood Taylor CEO |
BUY
Open market or private purchase
|
Direct |
11,000
+50.0%
|
$308,000
$28.99 P/Share
|
|
Oct 06
2023
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
217
-2.39%
|
$6,510
$30.46 P/Share
|
|
Oct 06
2023
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
738
+7.52%
|
$22,140
$30.46 P/Share
|
|
Aug 15
2023
|
Albert Manzone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,630
-48.01%
|
$99,940
$38.88 P/Share
|
|
Aug 15
2023
|
Albert Manzone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,478
+50.0%
|
$208,164
$38.88 P/Share
|
|
Jul 07
2023
|
Kyle Hanson EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,643
-18.79%
|
$116,576
$32.63 P/Share
|
|
Jul 07
2023
|
Kyle Hanson EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
12,409
+35.95%
|
$397,088
$32.63 P/Share
|
|
Jul 07
2023
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-3.15%
|
$8,672
$32.63 P/Share
|
|
Jul 07
2023
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
920
+9.65%
|
$29,440
$32.63 P/Share
|
|
Jun 13
2023
|
Geoffrey M. Parker Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+27.87%
|
$330,000
$33.06 P/Share
|
|
Jun 07
2023
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,104
-24.36%
|
$36,432
$33.72 P/Share
|
|
Jun 07
2023
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,532
+50.0%
|
$149,556
$33.72 P/Share
|
|
May 23
2023
|
Svend Andersen EVP & President CHCI |
BUY
Open market or private purchase
|
Direct |
2,900
+4.05%
|
$95,700
$33.41 P/Share
|
|
May 17
2023
|
Erica L Mann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,734
-22.45%
|
$119,488
$32.86 P/Share
|
|
May 17
2023
|
Erica L Mann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,778
+31.86%
|
$248,896
$32.86 P/Share
|
|
May 17
2023
|
Bradley A Alford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,734
-10.61%
|
$119,488
$32.86 P/Share
|
|
May 17
2023
|
Bradley A Alford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,778
+18.1%
|
$248,896
$32.86 P/Share
|
|
May 17
2023
|
Adriana Karaboutis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,734
-17.24%
|
$119,488
$32.86 P/Share
|
|
May 17
2023
|
Adriana Karaboutis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,778
+26.43%
|
$248,896
$32.86 P/Share
|